Mycophenolatmofetil Accord (Mycophenolate Mofetil)

Mycophenolate mofetil selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). This enzyme is essential for the synthesis of guanosine nucleotides in lymphocytes. By blocking this pathway, the drug reduces the proliferation of B and T cells, thereby dampening the immune response that can lead to organ rejection or autoimmune damage.

The dosage of Mycophenolatmofetil Accord is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and other individual factors. Healthcare professionals adjust the dose to achieve the desired immunosuppressive effect while minimizing adverse reactions.

Mycophenolate mofetil is classified as pregnancy category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless the potential benefit justifies the risk. Breastfeeding is also not recommended because the drug can be excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Compared with calcineurin inhibitors such as tacrolimus or cyclosporine, mycophenolate mofetil offers a different mechanism—targeting nucleotide synthesis rather than calcineurin signaling. It is often used in combination regimens to provide synergistic immunosuppression while allowing lower doses of each agent, potentially reducing individual drug toxicity.

The product should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the solution is prepared for immediate use, it should be administered promptly and any unused portion discarded according to local regulations.

Mycophenolatmofetil Accord is supplied as an intravenous solution. It is administered by a qualified healthcare professional through a controlled IV infusion, following the prescribing information for infusion rate and monitoring. The exact administration schedule is set by the treating physician.

Serious risks include severe infections due to immunosuppression, leukopenia or other blood dyscrasias, potential development of malignancies, hepatic dysfunction, and rare pulmonary toxicity. Patients should be monitored regularly for signs of infection, blood count changes, liver enzyme elevations, and respiratory symptoms.

Mycophenolatmofetil Accord is contraindicated in patients with known hypersensitivity to mycophenolate mofetil or any component of the formulation. It should also be avoided in pregnant women unless absolutely necessary, and in individuals with uncontrolled infections or severe hepatic impairment without careful risk assessment.